Discovery & development of selective M3 antagonists for clinical use.
about
Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary diseaseStructural basis of stereospecific reduction by quinuclidinone reductaseSelective antagonism of muscarinic receptors is neuroprotective in peripheral neuropathyPopulation pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailabilityAssessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic dataNovel approaches and targets for treatment of chronic obstructive pulmonary disease.The pharmacological treatment of urinary incontinence.The muscarinic M(5) receptor: a silent or emerging subtype?New perspectives in asthma treatment.Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humansPharmacological agents for the treatment of urinary incontinence due to overactive bladder.Tiotropium bromide.Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.New therapies for chronic obstructive pulmonary diseaseDrugs in clinical development for chronic obstructive pulmonary disease.Emerging drugs for the treatment of chronic obstructive pulmonary disease.Management of overactive bladder syndromeBiological targets for therapeutic interventions in COPD: clinical potentialBehavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological TreatmentNew therapies for chronic obstructive pulmonary disease.Expression, purification, crystallization and X-ray analysis of 3-quinuclidinone reductase from Agrobacterium tumefaciens.Crystallization and preliminary X-ray analysis of the NADPH-dependent 3-quinuclidinone reductase from Rhodotorula rubra.(R)-(-)-Quinuclidin-3-ol.Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects.M1 is a major subtype of muscarinic acetylcholine receptors on mouse colonic epithelial cells.Study of the metabolites of bencycloquidium bromide racemate, a novel anticholinergic compound, in rat bile by liquid chromatography-tandem mass spectrometry.Determination of bencycloquidium bromide, a novel anticholinergic compound, in rat tissues by liquid chromatography-electrospray ionization mass spectrometry.
P2860
Q24250271-992381BD-E0B1-4A97-BF3C-CA6554A31772Q27681630-6EE95BC7-B943-443E-B701-FA745FA81E4EQ30836715-B7F6CBBF-7927-45C7-A098-DF778EFBB1F8Q30884154-9E2B087B-727E-4CEB-A9AB-F56145FE7F4CQ30891304-F1332670-7207-4057-8E20-9458E7E0C99DQ33771480-88E3111C-3B91-4416-B97A-629823B9B1E5Q33778812-63256534-E3AF-46AA-A3F6-53D7CF9210E2Q33898782-1C71577D-EBAB-48B0-8B17-6CE7BD09EDFFQ33987222-03F8DED0-960C-442F-91B9-A4D543ABF3D7Q33994796-D0101E8A-F7A5-41B2-BB58-0996D073BC7EQ34104589-4B246D7B-595B-4489-A0E0-0B8E7369E234Q34204383-57270A25-68DB-400C-8F3D-91E19EB21B34Q35183599-B6327919-B440-47D1-A164-2A61130E0E59Q35563923-02F6D3DA-E065-4FCE-8CDB-7927ADEB2B04Q36064621-2DE6C39A-ADCD-48BF-ABE1-87D1A6BB066EQ36458412-6697D8AF-CC68-4638-9367-9648F61A7A9DQ36875672-9A9E2C40-75A2-4721-9111-F570F9DFBA77Q37018843-4A32B2DA-AF04-4258-A5CC-ACDCAA1EF934Q37484824-718CEB94-3D73-438B-BA1D-B51ABE77C3FEQ38032608-E0479EF5-1148-40DA-83CE-A4E94D43A73CQ38860110-86DC6653-7CEE-46EB-9C4B-9A32EB3B001AQ40525688-49E3E2E4-D6E9-4843-BE14-A81E05724282Q41157006-AE7EFB62-6884-422C-BCBD-47C0C8018B15Q41850829-932FD294-B3DC-43CE-89E2-7E3DA8A11579Q41857571-737A33BA-6BB5-4884-804D-8C37F20E1B09Q43358602-69BDBA01-5089-4A8B-AFD0-1E8D87E4727EQ44928100-E8155BF0-558C-40A4-A07A-1285D4EB89FAQ46584991-C5B1BB34-B70C-4E03-AFBF-767B87116A81Q48819152-6674580C-E85F-40B2-A834-DE17A2454DDA
P2860
Discovery & development of selective M3 antagonists for clinical use.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Discovery & development of selective M3 antagonists for clinical use.
@en
type
label
Discovery & development of selective M3 antagonists for clinical use.
@en
prefLabel
Discovery & development of selective M3 antagonists for clinical use.
@en
P1433
P1476
Discovery & development of selective M3 antagonists for clinical use.
@en
P2093
Alabaster VA
P304
P356
10.1016/S0024-3205(97)00047-7
P407
P577
1997-01-01T00:00:00Z